Context Therapeutics Inc. (CNTX)
$0.26-7.14%Close
SELLCRISIS · day 14
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $24M
- Beta
- 1.72
- P/E (TTM)
- -0.53
- Short % float
- 7.28%
- Days to cover
- 4.0
- SI change
- -31.8%
- 1W
- -16.13%
- 1M
- -27.78%
- vs SPY 1W
- -15.99%
- vs SPY 1M
- -30.28%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 18
- VALUE
- 32
- GROWTH
- 47
- GARP
- 6
- TYPE
- Value / Recovery
Composite of Value · Growth · GARP
ROIC-49.2%
REV YoY-
ROE-82.1%
EPS YoY-
ROA-99.6%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.53
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B0.64
P/FCF-
EV/EBITDA0.42
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.64
ALTMAN Z-
CURR RATIO5.81
ND/EBITDA-
BETA1.72
Company news
FAQ
- What is LOPJLB’s current signal on CNTX?
- LOPJLB’s latest quantitative signal on Context Therapeutics Inc. (CNTX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is CNTX in?
- Context Therapeutics Inc. (CNTX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Context Therapeutics Inc. (CNTX) do?
- Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the develo…